Skip to Main Content

Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release

Conditions

Hodgkin's Lymphoma | Lymphoid Leukemia | Non-Hodgkin's Lymphoma

Phase Expanded Access

What is the purpose of this trial?

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.

  • Trial with
    Novartis Pharmaceuticals
  • Start Date
    08/19/2019
  • End Date
    04/30/2021
Trial Image

For more information about this study, contact:

Laura Leary

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/21/2019
  • Study HIC
    #2000025634